OMass applying gas mass spec tech to human health with $18M series A round

Published

November 27, 2018

OMass applying gas mass spec tech to human health with $18M series A round

OMass Therapeutics Ltd. has closed a £14 million (US$18 million) series A round, equipping it to commence commercialization of a new gas phase mass spectrometry technology with which it is possible to study the binding of small molecules to intact protein assemblies…

MORERelated News
Is big pharma falling back in love with small molecules?
New approaches to small-molecule design allow difficult targets to be addressed, such as the G protein-coupled receptors (GPCR) on cell...
Women in Bio: OMass Taps Biogen Vet Nathalie Franchimont for Board of Directors
When U.K.-based OMass Therapeutics began the search for a new member for its board of directors, Chief Executive Officer Rosamond...
UK biotech OMass raises £27.5m for GPCR drug discovery
Oxford, UK-based OMass Therapeutics has extended its first-round financing to more than £41 million ($53 million), to help it fund...